170 related articles for article (PubMed ID: 38774225)
1. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China.
Yuan L; Luo Y; Luo Y; Ding B; Zhang P; Ma J; Wu J
Front Endocrinol (Lausanne); 2024; 15():1364585. PubMed ID: 38774225
[TBL] [Abstract][Full Text] [Related]
2. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.
Blevins T; Zhang Q; Frias JP; Jinnouchi H; Chang AM;
Diabetes Care; 2020 Dec; 43(12):2991-2998. PubMed ID: 32616612
[TBL] [Abstract][Full Text] [Related]
3. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial.
Zhou J; Chen S; Cheng J; Zhu J; Lou Y; Bao Y; Jia W
Sci Bull (Beijing); 2022 Sep; 67(17):1785-1791. PubMed ID: 36546064
[TBL] [Abstract][Full Text] [Related]
4. Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study.
Ma J; Yan X; Feng Q; Liu W; Pérez Manghi F; García-Hernández P; Wang G; Xu J; Yuan Y; Zhou Z
Diabetes Obes Metab; 2024 Jan; 26(1):311-318. PubMed ID: 37871985
[TBL] [Abstract][Full Text] [Related]
5. Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy.
Malecki MT; Cao D; Liu R; Hardy T; Bode B; Bergenstal RM; Bue-Valleskey J
Diabetes Technol Ther; 2020 Nov; 22(11):853-860. PubMed ID: 32453647
[No Abstract] [Full Text] [Related]
6. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study.
Klaff L; Cao D; Dellva MA; Tobian J; Miura J; Dahl D; Lucas J; Bue-Valleskey J
Diabetes Obes Metab; 2020 Oct; 22(10):1799-1807. PubMed ID: 32488923
[TBL] [Abstract][Full Text] [Related]
7. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.
Warren M; Bode B; Cho JI; Liu R; Tobian J; Hardy T; Chigutsa F; Phillip M; Horowitz B; Ignaut D
Diabetes Obes Metab; 2021 Jul; 23(7):1552-1561. PubMed ID: 33687783
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of ultra rapid lispro in the treatment of type 2 diabetes mellitus: a randomized controlled clinical trial].
Chen S; Zhou J; Lu JY; Bao YQ; Xu JW; Zhu JK; Jia WP
Zhonghua Nei Ke Za Zhi; 2023 Sep; 62(9):1093-1101. PubMed ID: 37650183
[No Abstract] [Full Text] [Related]
9. Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis.
Jinnouchi H; Imori M; Nishiyama H; Imaoka T
Diabetes Ther; 2020 Sep; 11(9):2075-2088. PubMed ID: 32728833
[TBL] [Abstract][Full Text] [Related]
10. Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes.
Bergenstal RM; Bode BW; Bhargava A; Wang Q; Knights AW; Chang AM
Diabetes Ther; 2023 Nov; 14(11):1933-1945. PubMed ID: 37740871
[TBL] [Abstract][Full Text] [Related]
11. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study.
Zhang Q; Chigutsa F; Chang AM
Diabetes Ther; 2022 Aug; 13(8):1547-1557. PubMed ID: 35781789
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial.
Wadwa RP; Laffel LM; Franco DR; Dellva MA; Knights AW; Pollom RK
Diabetes Obes Metab; 2023 Jan; 25(1):89-97. PubMed ID: 36054737
[TBL] [Abstract][Full Text] [Related]
14. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
Leohr J; Kazda C; Liu R; Reddy S; Dellva MA; Matzopoulos M; Loh MT; Hardy T; Klein O; Kapitza C
Diabetes Obes Metab; 2022 Feb; 24(2):187-195. PubMed ID: 34605142
[TBL] [Abstract][Full Text] [Related]
15. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
Leohr J; Dellva MA; LaBell E; Coutant DE; Klein O; Plum-Moerschel L; Zijlstra E; Linnebjerg H
Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
[TBL] [Abstract][Full Text] [Related]
17. Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog
Miura J; Imori M; Nishiyama H; Imaoka T
Diabetes Ther; 2020 Sep; 11(9):2089-2104. PubMed ID: 32728832
[TBL] [Abstract][Full Text] [Related]
18. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.
Bode BW; Garg SK; Norwood P; Morales C; Hardy T; Liu R; Ignaut D
Diabetes Technol Ther; 2021 Jan; 23(1):41-50. PubMed ID: 32640842
[No Abstract] [Full Text] [Related]
19. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
20. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
